mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2024-2-75-80mrj-1565Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL OBSERVATIONSПервый клинический опыт применения селективной плазмосорбции ДНК с использованием сорбционной колонки «НуклеоКор®» при лечении системной красной волчанкиThe first clinical experience with selective DNA plasmasorption using the NucleoCapture Device in the treatment of systemic lupus erythematosushttps://orcid.org/0000-0002-1663-7810АсееваЕ. А.AseevaE. A.

Елена Александровна Асеева

115522, Москва, Каширское шоссе, 34А

Elena Aleksandrovna Aseeva

34A, Kashirskoe Shosse, Moscow 115522

   

eaasseeva@mail.ruhttps://orcid.org/0000-0001-5105-0313ПокровскийН. С.PokrovskyN. S.

121552, Москва, ул. Академика Чазова, 15А

121552, Москва, ул. Кулакова, 20, стр. 1

   

15A, Academician Chazov Street, Moscow 121552

20, Kulakov Street, Build. 1, Moscow 121552

   

https://orcid.org/0000-0002-5206-1732СоловьевС. К.SolovievS. K.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

https://orcid.org/0000-0002-6906-0621НиколаеваЕ. В.NikolaevaE. V.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

https://orcid.org/0000-0002-4160-7218НикишинаН. Ю.NikishinaN. Yu.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

https://orcid.org/0009-0006-8106-8091АбдуллинЕ. Т.AbdullinE. T.

121552, Москва, ул. Кулакова, 20, стр. 1

119991, Москва, Ломоносовский просп., 27

20, Kulakov Street, Build. 1, Moscow 121552

27, Lomonosovsky Prospect, Moscow 119991

https://orcid.org/0000-0003-3552-2522РешетнякТ. М.ReshetnyakT.  M.

115522, Москва, Каширское шоссе, 34А

125993, Москва, ул. Баррикадная, 2/1, стр. 1

34A, Kashirskoe Shosse, Moscow 115522

2/1, Barrikadnaya Street, Build. 1, Moscow 125993

https://orcid.org/0000-0002-4579-2836ЗоткинЕ. Г.ZotkinE. G.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

https://orcid.org/0000-0002-6068-3080ЛилаА. М.LilaA. M.

115522, Москва, Каширское шоссе, 34А

125993, Москва, ул. Баррикадная, 2/1, стр. 1

34A, Kashirskoe Shosse, Moscow 115522

2/1, Barrikadnaya Street, Build. 1, Moscow 125993

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГБУ «Национальный медицинский исследовательский центр кардиологии им. акад. Е.И. Чазова» Минздрава России; ООО НПФ «ПОКАРД»РоссияNational Medical Research Centre of Cardiology named after Academician E.I. Chazov, Ministry of Health of Russia; “POKARD” Research and Production Company LLC, MoscowRussian FederationООО НПФ «ПОКАРД»; ФГОУ ВПО «Московский государственный университет им. М.В. Ломоносова»Россия“POKARD” Research and Production Company LLC; Lomonosov Moscow State UniversityRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; кафедра ревматологии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияV.A. Nasonova Research Institute of Rheumatology; Department of Rheumatology Russian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaRussian Federation2024220420241827580Copyright © Асеева Е.А., Покровский Н.С., Соловьев С.К., Николаева Е.В., Никишина Н.Ю., Абдуллин Е.Т., Решетняк Т.М., Зоткин Е.Г., Лила А.М., 20242024Асеева Е.А., Покровский Н.С., Соловьев С.К., Николаева Е.В., Никишина Н.Ю., Абдуллин Е.Т., Решетняк Т.М., Зоткин Е.Г., Лила А.М.Aseeva E.A., Pokrovsky N.S., Soloviev S.K., Nikolaeva E.V., Nikishina N.Y., Abdullin E.T., Reshetnyak T.M., Zotkin E.G., Lila A.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1565

Системная красная волчанка (СКВ) – системное аутоиммунное заболевание неизвестной этиологии, для которого характерна гиперпродукция аутоантител к различным компонентам ядра собственных клеток с развитием иммуновоспалительного повреждения тканей. В последние годы накапливается все больше данных об участии нейтрофилов в развитии клинических симптомов СКВ, и значимую роль в этом процессе играют ДНК-содержащие структуры и нейтрофильные внеклеточные ловушки (НВЛ). Эффективная нейтрализация НВЛ при СКВ может быть достигнута с помощью удаления из кровотока ассоциированных с НВЛ циркулирующих белков и молекул при проведении селективной плазмосорбции ДНК с использованием сорбционной колонки «НуклеоКор®».

В статье представлено описание пациентки, которой проведено три сеанса плазмосорбции для купирования активности СКВ. На фоне терапии достигнута значительная положительная динамика: индекс SLEDAI-2K снизился с 32 до 12 баллов, нормализовалось число лейкоцитов крови, улучшилась почечная функция и уменьшилась иммунологическая активность заболевания.

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease of unknown etiology characterized by the overproduction of autoantibodies against various components of the nucleus of the patient's own cells with the development of immunoinflammatory tissue damage. In recent years, more and more data have accumulated on the involvement of neutrophils in the development of the clinical symptoms of SLE, and DNA-containing structures and neutrophil extracellular traps (NETs) playing an important role in this process. Effective neutralization of NETs in SLE can be achieved by removing circulating proteins and molecules associated with NETs from the bloodstream by selective plasma sorption of DNA using the NucleoCapture Device.

This article describes the case of a patient who underwent three plasma sorption sessions aiming to suppress the activity of SLE. During the therapy, significant positive dynamics were achieved: the SLEDAI-2K index decreased from 32 to 12 points, the number of leukocytes in the blood normalized, renal function improved, and the immunological activity of the disease decreased.

системная красная волчанканейтрофильные внеклеточные ловушкивнеклеточная ДНКселективная плазмосорбцияиммуносорбциясорбционная колонка «НуклеоКор®»systemic lupus erythematosusneutrophil extracellular trapsextracellular DNAselective plasmasorptionimmunosorptionNucleoCapture DeviceИсследование проведено при поддержке ООО НПФ «ПОКАРД».The study was conducted with the support of “POKARD” Research and Production Company LLC.ReferencesKaul A, Gordon C, Crow MK, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016 Jun 16:2:16039. doi:10.1038/nrdp.2016.39.Kaul A, Gordon C, Crow MK, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016 Jun 16:2:16039. doi:10.1038/nrdp.2016.39.Насонов ЕЛ, Авдеева АС, Решетняк ТМ и др. Роль нетоза в патогенезе иммуновоспалительных ревматических заболеваний. Научно-практическая ревматология. 2023;61(5):513-530.Nasonov EL, Avdeeva AS, Reshetnyak TM, et al. The role of netosis in the pathogenesis of immuno-inflammatory rheumatic diseases. Nauchno-prakticheskaya revmatologiya. 2023;61(5):513-530. (In Russ.)].Tsokos GC. Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol. 2020 Jun;21(6):605-614. doi: 10.1038/s41590-020-0677-6. Epub 2020 May 4.Tsokos GC. Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol. 2020 Jun;21(6):605-614. doi: 10.1038/s41590-020-0677-6. Epub 2020 May 4.Crow MK. Pathogenesis of systemic lupuserythematosus: Risks,mechanisms and therapeutic targets. Ann Rheum Dis. 2023 Aug; 82(8):999-1014. doi: 10.1136/ard-2022223741. Epub 2023 Feb 15.Crow MK. Pathogenesis of systemic lupuserythematosus: Risks,mechanisms and therapeutic targets. Ann Rheum Dis. 2023 Aug; 82(8):999-1014. doi: 10.1136/ard-2022223741. Epub 2023 Feb 15.Насонов ЕЛ, Авдеева АС. Иммуновоспалительные ревматические заболевания, связанные с интерфероном типа I: новые данные. Научно-практическая ревматология.2019;57(4):452-461.Nasonov EL, Avdeeva AS. Immuno-inflammatory rheumatic diseases associated with interferon type I: new data. Nauchno-prakticheskaya revmatologiya. 2019;57(4):452-461. (In Russ.)].Psarras A, Wittmann M, Vital EM. Emerging concepts of type I interferons in SLE pathogenesis and therapy. Nat Rev Rheumatol. 2022 Oct;18(10):575-590. doi: 10.1038/s41584-022-00826-z. Epub 2022 Sep 12.Psarras A, Wittmann M, Vital EM. Emerging concepts of type I interferons in SLE pathogenesis and therapy. Nat Rev Rheumatol. 2022 Oct;18(10):575-590. doi: 10.1038/s41584-022-00826-z. Epub 2022 Sep 12.Ma S, Jiang W, Zhang X, Liu W. Insightsinto the pathogenic role of neutrophils in systemic lupus erythematosus. Curr Opin Rheumatol. 2023 Mar 1;35(2):82-88. doi: 10.1097/BOR.0000000000000912. Epub 2022 Oct 14.Ma S, Jiang W, Zhang X, Liu W. Insightsinto the pathogenic role of neutrophils in systemic lupus erythematosus. Curr Opin Rheumatol. 2023 Mar 1;35(2):82-88. doi: 10.1097/BOR.0000000000000912. Epub 2022 Oct 14.Banchereau R, Hong S, Cantarel B, et al.Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell. 2016 Apr 21;165(3):551-65. doi: 10.1016/j.cell.2016.03.008. Epub 2016 Mar 31.Banchereau R, Hong S, Cantarel B, et al.Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell. 2016 Apr 21;165(3):551-65. doi: 10.1016/j.cell.2016.03.008. Epub 2016 Mar 31.Gestermann N, Di Domizio J, Lande R, et al. Netting neutrophils activate autoreactive B cells in lupus. J Immunol. 2018 May 15; 200(10):3364-3371. doi: 10.4049/jimmunol.1700778. Epub 2018 Apr 9.Gestermann N, Di Domizio J, Lande R, et al. Netting neutrophils activate autoreactive B cells in lupus. J Immunol. 2018 May 15; 200(10):3364-3371. doi: 10.4049/jimmunol.1700778. Epub 2018 Apr 9.Petretto A, Bruschi M, Pratesi F, et al. Neutrophil extracellular traps (NET) induced by different stimuli: A comparative proteomic analysis. PLoS One. 2019 Jul 8;14(7):e0218946. doi: 10.1371/journal.pone.0218946.eCollection 2019.Petretto A, Bruschi M, Pratesi F, et al. Neutrophil extracellular traps (NET) induced by different stimuli: A comparative proteomic analysis. PLoS One. 2019 Jul 8;14(7):e0218946. doi: 10.1371/journal.pone.0218946.eCollection 2019.Apel F, Andreeva L, Knackstedt LS, et al. The cytosolic DNA sensor cGAS recognizes neutrophil extracellular traps. Sci Signal. 2021 Mar 9;14(673):eaax7942. doi: 10.1126/scisignal.aax7942.Apel F, Andreeva L, Knackstedt LS, et al. The cytosolic DNA sensor cGAS recognizes neutrophil extracellular traps. Sci Signal. 2021 Mar 9;14(673):eaax7942. doi: 10.1126/scisignal.aax7942.Tumurkhuu G, Chen S, Montano EN, et al. Oxidative DNA damage accelerates skin inflammation in pristane-induced lupus model. Front Immunol. 2020 Sep 24:11:554725. doi: 10.3389/fimmu.2020.554725.eCollection 2020.Tumurkhuu G, Chen S, Montano EN, et al. Oxidative DNA damage accelerates skin inflammation in pristane-induced lupus model. Front Immunol. 2020 Sep 24:11:554725. doi: 10.3389/fimmu.2020.554725.eCollection 2020.Gehrke N, Mertens C, Zillinger T, et al. Oxidative damage of DNA confers resistance to cytosolic nuclease TREX1 degradation and potentiates STING-dependent immune sensing. Immunity. 2013 Sep 19;39(3):482-95. doi: 10.1016/j.immuni.2013.08.004. Epub 2013 Aug 29.Gehrke N, Mertens C, Zillinger T, et al. Oxidative damage of DNA confers resistance to cytosolic nuclease TREX1 degradation and potentiates STING-dependent immune sensing. Immunity. 2013 Sep 19;39(3):482-95. doi: 10.1016/j.immuni.2013.08.004. Epub 2013 Aug 29.Chauhan SK, Rai R, Singh VV, et al. Differential clearance mechanisms, neutrophil extracellular trap degradation and phagocytosis, are operative in systemic lupus erythematosus patients with distinct autoantibody specificities. Immunol Lett. 2015 Dec;168(2): 254-9. doi: 10.1016/j.imlet.2015.09.016. Epub 2015 Oct 3.Chauhan SK, Rai R, Singh VV, et al. Differential clearance mechanisms, neutrophil extracellular trap degradation and phagocytosis, are operative in systemic lupus erythematosus patients with distinct autoantibody specificities. Immunol Lett. 2015 Dec;168(2): 254-9. doi: 10.1016/j.imlet.2015.09.016. Epub 2015 Oct 3.Gupta AK, Giaglis S, Hasler P, Hahn S.Efficient neutrophil extracellular trap induction requires mobilization of both intracellular and extracellular calcium pools and is modulated by cyclosporine A. PLoS One. 2014 May 12;9(5):e97088. doi: 10.1371/journal.pone.0097088.eCollection 2014.Gupta AK, Giaglis S, Hasler P, Hahn S.Efficient neutrophil extracellular trap induction requires mobilization of both intracellular and extracellular calcium pools and is modulated by cyclosporine A. PLoS One. 2014 May 12;9(5):e97088. doi: 10.1371/journal.pone.0097088.eCollection 2014.Lachmann PJ. The treatment of systemiclupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone. Clin Exp Immunol. 1996 Nov;106(2):243-52. doi: 10.1046/j.1365-2249.1996.d01-839.x.Lachmann PJ. The treatment of systemiclupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone. Clin Exp Immunol. 1996 Nov;106(2):243-52. doi: 10.1046/j.1365-2249.1996.d01-839.x.Macanovic M, Sinicropi D, Shak S, et al. Recombinant human Dnase I (rhDNase) in patients with lupus nephritis. Lupus. 1999;8(1): 68-76. doi: 10.1191/096120399678847380.Macanovic M, Sinicropi D, Shak S, et al. Recombinant human Dnase I (rhDNase) in patients with lupus nephritis. Lupus. 1999;8(1): 68-76. doi: 10.1191/096120399678847380.Ngo ATP, Gollomp K. Building a betterNET: Neutrophil extracellular trap targeted therapeutics in the treatment of infectious and inflammatory disorders. Res Pract Thromb Haemost. 2022;6:e12808. doi: 10.1002/rth2.12808Ngo ATP, Gollomp K. Building a betterNET: Neutrophil extracellular trap targeted therapeutics in the treatment of infectious and inflammatory disorders. Res Pract Thromb Haemost. 2022;6:e12808. doi: 10.1002/rth2.12808Huang J, Hong W, Wan M, Zheng L. Molecular mechanisms and therapeutic target of NETosis in diseases. MedComm (2020). 2022 Aug 19;3(3):e162. doi: 10.1002/mco2.162.eCollection 2022 Sep.Huang J, Hong W, Wan M, Zheng L. Molecular mechanisms and therapeutic target of NETosis in diseases. MedComm (2020). 2022 Aug 19;3(3):e162. doi: 10.1002/mco2.162.eCollection 2022 Sep.Baker KF, Isaacs JD. Novel therapies forimmune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann Rheum Dis. 2018 Feb; 77(2):175-187. doi: 10.1136/annrheumdis2017-211555. Epub 2017 Aug 1.Baker KF, Isaacs JD. Novel therapies forimmune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann Rheum Dis. 2018 Feb; 77(2):175-187. doi: 10.1136/annrheumdis2017-211555. Epub 2017 Aug 1.Насонов ЕЛ. Фармакотерапия ревматоидного артрита: новая стратегия, новые мишени. Научно-практическая ревматология. 2017;55(4):409-419.Nasonov EL. Pharmacotherapy of rheumatoid arthritis: new strategy, new targets. Nauchno-prakticheskaya revmatologiya. 2017;55(4):409-419. (In Russ.)].Aswani A, Abramovsky S, Afanasieva M,et al. Safety and Performance of the NucleoCapture Column for Selective cfDNA/NETs Apheresis in Patients with Sepsis (ClinicalTrials.gov Identifier: NCT04749238). Abstract Booklet. ISFA – E-ISFA; 2023. Р. 67.Aswani A, Abramovsky S, Afanasieva M,et al. Safety and Performance of the NucleoCapture Column for Selective cfDNA/NETs Apheresis in Patients with Sepsis (ClinicalTrials.gov Identifier: NCT04749238). Abstract Booklet. ISFA – E-ISFA; 2023. Р. 67.Абрамовский СВ , Иванова ГГ , Булдаков МЮ. Селективное удаление внеклеточной ДНК у больных с риском развития острого почечного повреждения. Клиническое исследование. XIX Cъезд Федерации анастезиологов и реаниматологов России (ФАРР-2021). Сборник тезисов – электронное издание. Санкт-Петербург: Человек и его здоровье; 2021. С. 6-7.Abramovskii SV , Ivanova GG , Buldakov MYu. Selective extracellular DNA removal in patients at risk of acute renal injury. A clinical trial. XIX S"ezd Federatsii anasteziologov i reanimatologov Rossii (FARR-2021). Sbornik tezisov – elektronnoe izdanie [XIX Congress of the Federation of Anesthesiologists and Intensive Care Specialists of Russia (FARR-2021). Collection of abstracts – electronic edition]. Sankt-Petersburg: Chelovek i ego zdorov'e; 2021. P. 6-7].Wang Y, Xiao S, Xia Y, Wang H. The Therapeutic Strategies for SLE by Targeting Anti-dsDNA Antibodies. Clin Rev Allergy Immunol. 2022 Oct;63(2):152-165. doi: 10.1007/s12016-021-08898-7. Epub 2021 Sep 20.Wang Y, Xiao S, Xia Y, Wang H. The Therapeutic Strategies for SLE by Targeting Anti-dsDNA Antibodies. Clin Rev Allergy Immunol. 2022 Oct;63(2):152-165. doi: 10.1007/s12016-021-08898-7. Epub 2021 Sep 20.Terman DS, Buffaloe G, Mattioli C, et al.Extracorporeal immunoadsorption: initial experience in human systemic lupus erythematosus. Lancet. 1979 Oct 20;2(8147):824-7. doi: 10.1016/s0140-6736(79)92177-9.Terman DS, Buffaloe G, Mattioli C, et al.Extracorporeal immunoadsorption: initial experience in human systemic lupus erythematosus. Lancet. 1979 Oct 20;2(8147):824-7. doi: 10.1016/s0140-6736(79)92177-9.Kronbichler A, Brezina B, Quintana LF, Jayne DR. Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: A systematic review. Autoimmun Rev. 2016 Jan; 15(1):38-49. doi: 10.1016/j.autrev.2015.08.010. Epub 2015 Aug 28.Kronbichler A, Brezina B, Quintana LF, Jayne DR. Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: A systematic review. Autoimmun Rev. 2016 Jan; 15(1):38-49. doi: 10.1016/j.autrev.2015.08.010. Epub 2015 Aug 28.Stummvoll GH. Immunoadsorption (IAS) for systemic lupus erythematosus. Lupus. 2011 Feb;20(2):115-9. doi: 10.1177/0961203310 389487.Stummvoll GH. Immunoadsorption (IAS) for systemic lupus erythematosus. Lupus. 2011 Feb;20(2):115-9. doi: 10.1177/0961203310 389487.Smith CK, Kaplan MJ. The role of neutrophils in the pathogenesis of systemic lupus erythematosus. Curr Opin Rheumatol. 2015 Sep;27(5):448-53. doi: 10.1097/BOR.0000000000000197Smith CK, Kaplan MJ. The role of neutrophils in the pathogenesis of systemic lupus erythematosus. Curr Opin Rheumatol. 2015 Sep;27(5):448-53. doi: 10.1097/BOR.0000000000000197Tay SH, Celhar T, Fairhurst AM. LowDensity Neutrophils in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2020 Oct; 72(10):1587-95. doi: 10.1002/art.41395. Epub 2020 Aug 26.Tay SH, Celhar T, Fairhurst AM. LowDensity Neutrophils in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2020 Oct; 72(10):1587-95. doi: 10.1002/art.41395. Epub 2020 Aug 26.Rahman S, Sagar D, Hanna RN, et al.Low-density granulocytes activate T cells and demonstrate a non-suppressive role in systemic lupus erythematosus. Ann Rheum Dis. 2019 Jul;78(7):957-66. doi: 10.1136/annrheumdis-2018-214620. Epub 2019 Apr 30.Rahman S, Sagar D, Hanna RN, et al.Low-density granulocytes activate T cells and demonstrate a non-suppressive role in systemic lupus erythematosus. Ann Rheum Dis. 2019 Jul;78(7):957-66. doi: 10.1136/annrheumdis-2018-214620. Epub 2019 Apr 30.Garcia-Romo GS, Caielli S, Vega B, et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med. 2011 Mar 9; 3(73):73ra20. doi: 10.1126/scitranslmed.3001201Garcia-Romo GS, Caielli S, Vega B, et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med. 2011 Mar 9; 3(73):73ra20. doi: 10.1126/scitranslmed.3001201Leffler J, Gullstrand B, Jönsen A, et al. Degradation of neutrophil extracellular traps co-varies with disease activity in patients with systemic lupus erythematosus. Arthritis Res Ther. 2013 Aug 14;15(4):R84. doi: 10.1186/ar4264.Leffler J, Gullstrand B, Jönsen A, et al. Degradation of neutrophil extracellular traps co-varies with disease activity in patients with systemic lupus erythematosus. Arthritis Res Ther. 2013 Aug 14;15(4):R84. doi: 10.1186/ar4264.

The authors declare that there are no conflicts of interest present.